| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2930 |
| Trial ID | NCT05236491 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Spikevax Bivalent Origina;Omicron BA.4/5|elasomeran|davesomeran;Novavax Nuvaxovid Vaccine |
| Phase | Phase2|Phase3 |
| Recruitment status | Recruiting |
| Title | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases |
| Year | 2022 |
| Country | Canada |
| Company sponsor | Paul R Fortin |
| Other ID(s) | COVB-2022-1 |
| Vector information | |||
|
|||
| Cohort1: SPIKEVAX Bivalent/Novavax Nuvaxovid | |||||||
|
|||||||
| Cohort2: No Intervention | |||||||
|
|||||||
| Cohort3: Novavax NUVAXOVID | |||||||
|
|||||||